No Data
Mizuho Securities Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Maintains Target Price $30
Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
Raymond James Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Cuts Target Price to $78
Jefferies Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $57
Apellis Pharmaceuticals: Buy Rating Affirmed Amid FDA Approval and Strategic Market Positioning
Oppenheimer Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $42
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
been hot today but that's getting into buying range for me..... EBS middle size company that got a new CEO last year completely changed things around since for EBS. take a look at who owns EBS and how much together. this small float is trading around 50% since half or more is already bought up by insiders or tutes
